Literature DB >> 19131976

Buzz around Campath proof-of-concept trial in MS.

Randy Osborne.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19131976     DOI： 10.1038/nbt0109-6

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Removal of T cells from bone marrow for transplantation. Comparison of rat monoclonal anti-lymphocyte antibodies of different isotypes.

Authors:  G Hale; T Hoang; T Prospero; S M Watt; H Waldmann
Journal:  Mol Biol Med       Date:  1983-10

2.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245
  2 in total
  2 in total

Review 1.  Neurological disorders and therapeutics targeted to surmount the blood-brain barrier.

Authors:  Jagat R Kanwar; Bhasker Sriramoju; Rupinder K Kanwar
Journal:  Int J Nanomedicine       Date:  2012-07-09

Review 2.  Neurobehavioral burden of multiple sclerosis with nanotheranostics.

Authors:  Bhasker Sriramoju; Rupinder K Kanwar; Jagat R Kanwar
Journal:  Neuropsychiatr Dis Treat       Date:  2015-10-15       Impact factor: 2.570
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.